Understand the science. Vet the source.
Evidence-based roundups, transparent vendor scorecards, and a moderated research community — framed strictly for laboratory use.
Research Use Only — not for human or animal consumption.
Lab literacy
Plain-language explainers on COAs, HPLC vs. MS, sterility, endotoxin, and what RUO actually means.
Transparent vetting
A public methodology and scorecards that grade vendors on per-batch COAs, independent labs, purity, and consistency.
Moderated community
Threaded, research-only Q&A with voting, reputation, and active moderation. No sales, no human-use instructions.
Community
A moderated research forum
The forum is members-only. Sign in to browse categories, read threads, and join the conversation — research framing only.
Peptide library
Reference profiles, compound by compound
Class, targets, regulatory context, and links to cited literature roundups — structured like a lab notebook index, not marketing copy.
BPC-157
BPC-157 is a synthetic pentadecapeptide sequence derived from gastric-juice protein fragments. It is among the most discussed catalog peptides in connective-tissue and gastrointestinal preclinical literature — with a large but investigator-concentrated rodent bibliography.
Retatrutide
Retatrutide is a development-stage triple agonist adding glucagon receptor activity to dual incretin pharmacology. Human data are earlier and narrower than for semaglutide or tirzepatide, with active phase 2 literature.
Tirzepatide
Tirzepatide combines GIP and GLP-1 receptor agonism in a single acylated peptide — a distinct research object from GLP-1–selective molecules like semaglutide, with large published SURPASS and SURMOUNT trial programs.
Featured guides